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Abstract
Background
Illicit drug use is a multifaceted public-health problem with potentially serious impacts. The
United Kingdom has one of the highest prevalence of illegal drug use in Europe. Reduction
of overall illegal drug use in England and Wales has decreased from 11% to 8.2% (2012/13)
over the past 10 years. People who use drugs often seek help from their family doctors.
Aims
To investigate General Practitioners (family doctors) first recording of drug use and opioid
substitute treatment in primary care settings.
Design
A descriptive study design. Males and females (16-64 years old) were extracted from The
Health Improvement Network (THIN) database.
Setting
England andWales primary care.
Method
The first recording of drug use and opioid substitution treatment in primary care was estimat-
ed for the period (1994-2012). Poisson regressions were conducted to estimate incidence
risk ratios (IRR).
Results
We identified 33,508 first recordings of drug use and 10,869 individuals with prescriptions
for opioid substitute treatment. Overall, males (IRR 2.02, 95% CI:1.97–2.07), people in the
age-group; 16-24 (IRR 6.7, 95% CI:6.4–6.9) compared to those over 25 years and the most
deprived (IRR 4.2, 95% CI:3.9–4.4) were more likely to have a recording of drug use. Males
(IRR 1.2 95% CI:1.2–1.3), in the age-group; 25-34 (IRR 1.8 95% CI:1.7–1.9) and the most
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Conclusion
It is evident from this study that there is little recording of drug use and opioid substitute
treatment in primary care. Most drug users do not receive treatment in primary care.
Introduction
Illicit drug use is a public-health problem with serious impacts[1]. In 2012, between 162 and
324 million people had used an illegal drug globally [2]. The United Kingdom (UK) had the
second highest number of illegal drug seizures in Europe in 2012 [3]. According to the Crime
survey for England and Wales (CSEW), there has been a reduction in reported drug use from
11% in 2001/02 to 8.2% in 2012/13 [4]. Furthermore there has also been a reduction in problem
drug users in treatment and the use of heroin and crack cocaine between 2005 and 2011 [5].
These estimates are based on self-reports and hence may be subject to reporting bias. More-
over, they exclude prisoners, homeless people and students living in halls of residence [4,6,7].
The majority of people use drugs for recreational use and a small proportion become prob-
lem drug users and require treatment [5]. In England andWales, opioid substitute treatment is
controlled and therefore more effectively monitored [5]. Thus the Welsh drug misuse database
is used to monitor problem drug users in treatment in Wales [8] and in England, The National
Treatment Agency (NTA) was established as a special health authority in 2001 and became
part of Public Health England (PHE) in April 2013 [5]. Prevention and recovery of drug depen-
dency is incorporated in one of the top five health priorities for PHE 2013/2014 [9]. The Na-
tional Drug Treatment monitoring System monitors over 1,500 community treatment centres
which includes inpatient, outpatient and GP practices in England. Most of the National Treat-
ment Agency services are accessed via self-referral and other referral sources including the
NHS, the criminal justice system and GPs [5].
Previous research on recording of drug misuse in general practice using the General Practice
Research Database (GPRD) from 1998 to 2005 suggested a decline in recording which could be
due to a decrease in overall drug misuse, although it was acknowledged that these results may
be influenced by other factors [10]. Another study, also used the GPRD, but examined opiate
substitution in primary care and the risk of death from 1990 to 2005 [11]. The results highlight-
ed the need for awareness of increased mortality risk when starting opioid substitute treatment
and premature withdrawal of substance abuse medication [11].
In this study we sought to assess more recent changes that may have occurred in recording.
We therefore aimed to further describe contemporary GP recording of people who use drugs
and opioid substitute treatment in England andWales and compare these to national commu-
nity surveys (Crime Survey for England and Wales and National Treatment Agency) using a
large primary care database, The Health Improvement Network (THIN).
Methods
Ethical Approval
The National Health Service South-East Multicentre Research Ethics Committee granted ap-
proval for the THIN scheme to obtain and provide anonymous patient data for research in
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2003. The Medical Research Scientific Review Committee (set up in 2009 in the UK) approved
this study in 2013 (Approval number:13–026). Cegedim Strategic Data Medical Research UK
administers SRC application process.
Study design and data source
In the UK the majority of individuals (98%) are registered with a general practitioner [12]. In
total, 570 general practices contribute their data to THIN which incorporates approximately
6% of the UK population [13]. For this study we used data from the general practices located
in England and Wales (n = 460). During consultations, clinical information is entered in the
form of standardised Read codes, a hierarchical coding system together with drugs prescribed
onto the computer using Vision software [14]. THIN is comparable to the general UK popula-
tion in terms of demographics, mortality and prevalence of chronic and acute diseases, al-
though under 25s, males and less affluent individuals are slightly underrepresented compared
to the national statistics [15]. Social deprivation is recorded in THIN as quintile Townsend
scores [16]. Townsend scores are a measure of deprivation in the UK [16]. The score is created
by measuring four variables; household number, employment, ownership of car and home to
create a single measure of deprivation [17]. A higher score indicates the more deprived areas
[17]. The region of the general practice was divided into the former strategic health authorities
for England and country for Wales [18]. Different data quality markers and markers for prac-
tice computer usage have been developed to ensure recording death acceptable mortality re-
cording (AMR) [19] and acceptable computer usage (ACU) [20] and we applied these in
our study.
Study population and outcome measurements
We extracted information from all individuals who were aged between 16–64 years and perma-
nently registered with a general practice in England andWales which provided data to THIN
between January 1994 and December 2012. Patients are registered for different lengths of time
and we therefore use Patient years of exposure as our denominator. We have stratified analysis
by age and year. If a person has contributed 10 years of data, they will contribute person years
to individual age-bands. An example to illustrate this is if an individual was 18 in 2000 and
contributed 10 years of data, the individual will contribute to the 16–24 age-band until 2006
and then contribute to the 35–34 year age band. For each patient a GP can enter a Read code
and/or a drug code for a prescription in their computer system. We developed Read code and
drug code lists for individuals who use drugs and prescribed opioid substitute treatment ac-
cording to the methods described by Dave and Petersen, 2009 [21]. We used the following illicit
drugs and derivatives of these drugs as search terms: Amphetamine, cannabis, cocaine, crack
cocaine, crystal meth, heroin, inhalant, ketamine, khat, Lysergic acid diethylamide, magic
mushrooms, mandrax, mephedrone, methadrone, methamphetamine, methylone, naphyrone,
nitrites, phencyclidine, polydrug, sedative, solvent [22]. There are both Read codes indicating
drug use (n = 530) as well as Read codes for opioid substitute treatment (n = 43). We used the
following opioid substitute treatments as search terms for prescriptions; methadone, buprenor-
phine, naltrexone, naloxone and lofexidine [23,24]. Many drug users receive opioid substitute
treatment in the community rather than by their GP [5]. However, the GP may be aware that
they receive treatment and thus use these latter Read codes on their computer system. If a Read
code had an ambiguous meaning (e.g “drug tolerance”), we excluded it from the list. There
were 154 drug codes for prescriptions. For each prescription, we examined the dose for each
drug and included those which followed the recommended doses by the National Institute for
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Health and Care Excellence (NICE), Royal College of General Practitioners (RCGP) and Brit-
ish National Formularies (BNF) for detoxification programmes [25,26,23].
For some individuals, it was not entirely obvious if dihydrocodeine was prescribed for an in-
dication other than to treat substance misuse. In those situations we examined time between
prescriptions and individuals were only considered to receive that treatment against illicit drug
use if it were prescribed at intervals less than 35 days and dose greater than 450mg.
Individuals recorded as either using drugs and/or receiving opioid
substitution treatment
A first recorded case, was the first record for the individual in a particular calendar year. We
identified a group of people based on the first recording of: 1) Read code for either people who
use drugs and/or 2) Read code for opioid substitute treatment and/or 3) Prescription for opioid
substitute treatment between 1994–2012 and selected the first record for all individuals. We ex-
amined the association between people who use drugs and opioid substitute treatment and the
following covariates: gender, age, social deprivation and time period.
Statistical analysis
The socio-demographic profiles were summarised. Recording rates and 95% confidence in-
tervals of a new entry of an individual using drugs or receiving opioid substitute treatment
were estimated for each calendar year (1994–2012) taking into account the length of time
that each individual was registered with the general practice. Poisson regressions were con-
ducted to calculate the adjusted and unadjusted incidence rate ratios (IRR) of GP recording
of people who use drugs and/or opioid substitute treatment. We decided a priori on the basis
of the existing literature that age, gender and deprivation were confounders [3,4,10]. We ob-
served an effect modification by gender and therefore stratified the results of age, deprivation
and time period by gender. We used a forward stepwise approach and performed likelihood
ratio tests to select the most appropriate model. There was no evidence that region improved
the fit of the model (p = 0.08) and we therefore excluded this variable from our final model.
All data was analysed using STATA (version 13) statistical software (Stata Corp LP, College
Station, Texas).
Results
We identified 33,508 individuals with a record of drug use, 10,869 individuals with prescrip-
tions for opioid substitute treatment and 7,655 individuals with Read codes for opioid substi-
tute treatment. GPs used half (51%, n = 267) of the available Read codes for drug use in THIN.
A third (35% n = 7) of the 20 most frequently used codes were specific for the illicit drug. Only
18% (n = 27) of the available prescription codes and 72% (n = 31) of the possible Read codes
for opioid substitution treatment were used. Patients had different combinations of Read codes
and drug codes in their GP computer records (Fig 1), but relatively few individuals had entries
of all three. Hence, there were 28,179 (63.7%) individuals recorded as using drugs, but not re-
ceiving any opioid substitute treatment in primary care.
Overall there were more males than females with a record of using drugs and/or treatment.
Of those with a record for using drugs, most were between the ages of 16–24 years, from the
North East of England and of the most deprived group (Table 1). Fewer individuals had Read
or drug codes for opioid substitute treatment, but the regional and socio-demographic patterns
were similar, although they were slightly older and most of the individuals with a Read code for
treatment were from the North West of England (Table 1).
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Read codes for individuals who use drugs
Men were twice as likely to have a Read code in their electronic health records for drug use
when compared to women (IRR 2.0, 95% CI: 1.9–2.1). For men, compared to the oldest age
group, the youngest age group was almost seven times more likely to have a recording for drug
use (IRR 6.7, 95% CI: 6.4–6.9) (Table 2).
There was also a trend with regards to social deprivation, men from the most deprived areas
were four times more likely to have a drug use Read code recorded compared to those from
least deprived area (IRR 4.2, 95% CI:3.9–4.4) (Table 2). Recording of drug use was two times
more likely to occur during 1994–2000 compared to 2006–2012 (IRR 2.3, 95% CI: 2.2–2.4). For
women, the pattern was similar as for the men, though the contrasts were less stark (Table 2).
Opioid substitute treatment drug codes
There were more individuals with a record for drug use than those actually receiving opioid
substitute treatment. (Fig 2).
More men than women received opioid substitute treatment. (IRR 1.2, 95% CI: 1.2–1.3) and
also the most deprived group were more likely to have an opioid substitute treatment entry in
their notes (Table 3).
Men were slightly older (25–34 years) when they had their first entries for opioid substitute
treatment compared to when they had their first record of drug use entered in their electronic
Fig 1. Venn diagram depicting individuals with one, two or three of the Read and/ or Drug codes.
doi:10.1371/journal.pone.0122626.g001
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health records (Table 3 and Fig 3). Younger women compared to the 45–64 year age group
were less likely to have a code for opioid substitute treatment (Table 3).
There has been a decline in people receiving opioid substitute treatment in primary care.
Hence, both men (IRR 1.8, 95% CI: 1.7–1.9) and women (IRR 2.0, 95% CI: 1.8–2.2) were signif-
icantly more likely to receive a prescription between 1994–2000 compared to the period be-
tween 2006–2012.
Similar patterns were found for Read codes for opioid substitute treatment to those of the
drug codes (Higher IRR for males, 25–34 age group, most deprived and between 1994–2000)
(Table 4).
Discussion
Summary of main findings
The findings of this study illustrate that there are a number of individuals who are recognised
and have a record of drug use. However, if patients required treatment for their drug use, a
Table 1. Demographics, first recording rate (95%CI) for drug use Read codes and Opioid substitution treatment (OST) drug and Read codes by
gender, age-band, region and Townsend deprivation score.
Drug use Read code Opioid substitution treatment drug
code
Opioid substitution treatment Read
code
Demographics % (n) Rate (95% CI) OST drug code Rate (95% CI) OST Read code Rate (95% CI)
n = 33 508 % (n) n = 10 869 % (n) n = 7655
Gender
Males 67.5 (22,622) 1.49 (1.40–1.60) 61.8 (6721) 0.45 (0.39–0.51) 68.4(5241) 0.33 (0.28–0.370
Females 32.5 (10,886) 0.74 (0.67–0.82) 38.2 (4748) 0.35 (0.29–0.38) 31.6 (2414) 0.50 (0.42–0.56)
Age-band
16–24 31.8 (10,650) 2.47 (2.23–2.72) 14.2 (1,542) 0.43 (0.33–0.55) 19.4 (1,482) 0.34 (0.27–0.44)
25–34 32.8 (10,994) 1.76 (1.60–1.93) 28.7 (3,122) 0.53 (0.44–0.63) 44.1 (3,377) 0.50 (0.43–0.59)
35–44 20.0 (6,704) 0.88 (0.77–0.99) 24.1 (2,624) 0.37 (0.30–0.46) 25.7 (1,970) 0.24 (0.20–0.30)
45–64 15.4 (5,160) 0.41 (0.33–0.50) 32.9 (3,581) 0.33 (0.27–0.39) 10.8 (826) 0.06 (0.04–0.08)
Region
London 12.1 (4,051) 0.06 (0.05–0.07) 7.25 (788) 0.24 (0.16–0.34) 7.92 (606) 0.16 (0.11–0.24)
East Midlands 4.52 (1,514) 0.06 (0.04–0.07) 5.59 (608) 0.46 (0.30–0.69) 5.66 (433) 0.27 (0.17–0.43)
East of England 8.26 (2,768) 0.12 (0.11–0.13) 6.90 (750) 0.34 (0.22–0.49) 5.92 (453) 0.16 (0.10–0.26)
West Midlands 9.11 (3,051) 0.06 (0.05–0.06) 11.4 (1,243) 0.37 (0.28–0.50) 11.1 (851) 0.22 (0.16–0.31)
North East 3.75 (1,258) 0.15 (0.09–0.17) 5.14 (559) 0.64 (0.41–0.96) 4.10 (314) 0.29 (0.18–0.48)
North West 16.5 (5,513) 0.10 (0.09–0.11) 15.8 (1,721) 0.54 (0.42–0.68) 21.8 (1,669) 0.46 (0.37–0.57)
South Central 11.9 (3,990) 0.12 (0.10–0.15) 3.84 (417) 0.33 (0.25–0.44) 3.14 (240) 0.20 (0.15–0.27)
South East Coast 11.5 (3,865) 0.13 (0.12–0.15) 13.4 (1,459) 0.34 (0.24–0.48) 13.9 (1,063) 0.16 (0.11–0.26)
South West 9.29 (3,112) 0.05 (0.05–0.06) 10.3 (1,127) 0.46 (0.34–0.61) 7.04 (539) 0.24 (0.17–0.34)
Yorkshire&Humberside 3.61 (1,211) 0.05 (0.04–0.07) 12.5 (1,362) 0.35 (0.21–0.56) 10.2 (782) 0.18 (0.10–0.32)
Wales 9.48 (3,175) 0.09 (0.08–0.10) 7.68 (835) 0.38 (0.26–0.54) 9.21 (705) 0.27 (0.19–0.40)
Townsend deprivation
1(least deprived) 12.0 (3,825) 0.45 (0.38–0.53) 14.3 (1,475) 0.19 (0.15–0.25) 7.21 (526) 0.06 (0.04–0.09)
2 13.1 (4,200) 0.65 (0.56–0.76) 15.0 (1,552) 0.26 (0.20–0.34) 9.62 (696) 0.17 (0.11–0.25)
3 19.8 (6,321) 1.06 (0.93–1.20) 20.2 (2,092) 0.37 (0.29–0.47) 17.5 (1,275) 0.38 (0.27–0.52)
4 26.8 (8,571) 1.68 (1.50–1.88) 26.0 (2,691) 0.58 (0.47–0.71) 29.8 (2,166) 0.77 (0.59–1.02)
5(most deprived) 28.4 (9,076) 2.89 (2.59–3.21) 24.4 (2,526) 0.89 (0.72–1.09) 35.8 (2,604) 1.55 (1.24–1.96)
Rate = First recording rate/1000 person years at risk, OST = Opioid Substitution Treatment
doi:10.1371/journal.pone.0122626.t001
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large proportion of these patients did not receive treatment in primary care. Overall, there were
more males than females with records of drug use and of those with a record, most were be-
tween the ages of 16–24 years, residing in the North East of England and of the most deprived
group. First recording rates were significantly greater for men between the age-groups of 16–24
years (drug use) and 25–34 years (opioid substitute treatment) with high social deprivation
and between the period 1994–2000. In order to improve provision of care, we needed to have
Table 2. Unadjusted and adjusted Incidence Rate Ratios (95%CI) for drug use Read codes by age-band, deprivation, and time period (1994–2012).
Demographics Unadjusted IRR (95% CI) *Adjusted IRR (95% CI)
Males Females Males Females
Age-band
16–24 6.87 (6.58–7.17) 3.97 (3.77–4.19) 6.68 (6.39–6.99) 3.35 (3.17–3.55)
25–34 6.60 (6.32–6.89) 3.47 (3.28–3.66) 4.98 (4.76–5.21) 2.09 (1.98–2.22)
35–44 3.21 (3.06–3.36) 2.09 (1.97–2.12) 2.29 (2.18–2.41) 1.36 (1.28–1.44)
45–64 1 1 1 1
Townsend Score
1 (least deprived) 1 1 1 1
2 1.45 (1.37–1.53) 1.36 (1.26–1.47) 1.43 (1.36–1.51) 1.32 (1.22–1.43)
3 2.20 (2.10–2.31) 2.07 (1.93–2.22) 2.05 (1.95–2.16) 1.88 (1.75–2.02)
4 3.37 (3.22–3.54) 3.10 (2.89–3.31) 2.76 (2.63–2.89) 2.48 (2.32–2.66)
5(most deprived) 5.61 (5.36–5.88) 5.08 (4.76–5.42) 4.17 (3.98–4.37) 3.69 (3.46–3.95)
Time periods
1994–2000 2.30 (2.21–2.39) 2.32 (2.20–2.45) 2.29 (2.21–2.39) 2.28 (2.16–2.41)
2001–2006 1.75 (1.70–1.80) 1.69 (1.63–1.77) 1.74 (1.69–1.79) 1.71 (1.64–1.78)
2006–2012 1 1 1 1
*Adjusted for age deprivation, and time periods
doi:10.1371/journal.pone.0122626.t002
Fig 2. Combined first recording rates of Read (drug use) and Drug (opioid substitution treatment)
codes by age-group (in years) per 1000 person years at risk (1994–2012).
doi:10.1371/journal.pone.0122626.g002
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an understanding of the ongoing current recognition and recording in primary care and how
this has changed over time.
Strengths and Limitations
The main strength of this study is that THIN provides a large amount of data from real life pri-
mary care. This study, however, merely examines data that has been captured in primary care
and is not attempting to estimate a community incidence of the problem. There are some limi-
tations to our study. Firstly this study only covers individuals who have been in contact with
their GP in regards to their drug use. Many people use drugs for recreational use and only a
Table 3. Unadjusted and adjusted Incidence Rate Ratios (95%CI) for opioid substitution treatment drug codes by age-band, deprivation and time
period (1994–2012).
Demographics Unadjusted IRR(95% CI) *Adjusted IRR(95% CI)
Males Females Males Females
Age-band
16–24 1.38 (1.27–1.49) 0.89 (0.81–0.97) 1.22 (1.16–1.38) 0.78 (0.71–0.86)
25–34 2.72 (2.55–2.91) 1.39 (1.29–1.50) 1.84 (1.71–1.97) 0.86 (0.79–0.93)
35–44 1.82 (1.70–1.95) 1.16 (1.08–1.25) 1.58 (1.47–1.71) 0.79 (0.73–0.86)
45–64 1 1 1 1
Townsend Score
1 (least deprived) 1 1 1 1
2 1.40 (1.26–1.54) 1.34 (1.21–1.48) 1.37 (1.23–1.52) 1.31 (1.18–1.46)
3 2.07 (1.89–2.27) 1.66 (1.51–1.83) 1.98 (1.80–2.18) 1.59 (1.44–1.76)
4 3.10 (2.84–3.38) 2.29 (2.08–2.51) 2.75 (2.51–3.01) 2.08 (1.89–2.29)
5(most deprived) 4.86 (4.45–5.30) 3.01 (2.74–3.32) 3.92 (3.58–4.30) 2.55 (2.30–2.82)
Time periods
1994–2000 1.84 (1.71–1.97) 2.14 (1.97–2.32) 1.82 (1.69–1.97) 2.01 (1.84–2.19)
2001–2006 1.49 (1.41–1.58) 1.62 (1.52–1.73) 1.48 (1.39–1.57) 1.59 (1.49–1.71)
2006–2011 1 1 1 1
*Adjusted for age deprivation and time period
doi:10.1371/journal.pone.0122626.t003
Fig 3. Combined first recording rates of Read (drug use) and Drug (opioid substitution treatment)
codes by gender and age-group (in years) per 1000 person years at risk (1994–2012).
doi:10.1371/journal.pone.0122626.g003
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small percentage become problem drug users [5]. Drug use is stigmatised and discriminated
against in society [27]. This stigma may continue when drug users seek help for either stopping
their addiction or for obtaining replacement therapy [27]. Patients, therefore, may decide not
to disclose this information to a health professional. Disclosure may however occur when the
drug users’ behaviour causes harm and functional impairment [27]. GPs are also aware that
the patient-doctor relationship could be compromised if the patient is coded as a drug user
[28]. The majority of opioid substitute treatment for drug use occurs in the community drug
clinics, only a small proportion reach primary care and even a smaller proportion are recorded
electronically [5,29] (See Fig 4). Self-referral (40%) to community drug clinics is more common
Table 4. Unadjusted and adjusted Incidence Rate Ratios (95%CI) for opioid substitution treatment Read codes by age-band, deprivation and time
period (1994–2012).
Demographics Unadjusted IRR (95% CI) Adjusted IRR (95% CI)
Males Females Males Females
Age-band
16–24 4.46 (4.01–4.96) 5.94 (5.14–6.86) 4.64 (4.16–5.17) 4.85 (4.19–5.63)
25–34 10.3(9.40–11.31) 9.24(8.09–10.55) 7.87 (7.14–8.67) 5.09 (4.43–5.84)
35–44 5.39 (4.89–5.95) 4.05 (3.50–4.68) 3.79 (3.42–4.20) 2.49 (2.15–2.90)
45–64 1 1 1 1
Townsend Score
1 (least deprived) 1 1 1 1
2 1.74 (1.52–1.99) 1.64 (1.34–2.01) 1.69 (1.48–1.94) 1.57 (1.28–1.92)
3 3.03 (2.67–3.42) 3.42 (2.86–4.08) 2.72 (2.40–3.08) 2.97 (2.48–3.55)
4 5.89 (5.25–6.61) 6.11 (5.16–7.24) 4.66 (4.15–5.24) 4.59 (3.88–5.44)
5(most deprived) 11.2(10.0–12.6) 10.9(9.19–12.8) 8.21 (7.33–9.20) 7.51 (6.35–8.88)
Time
1994–2000 2.11 (1.94–2.30) 2.33 (2.05–2.65) 2.09 (1.91–2.28) 2.09 (1.91–2.28)
2001–2006 1.51 (1.43–1.61) 1.81 (1.66–1.97) 1.49 (1.39–1.58) 1.49 (1.39–1.58)
2006–2011 1 1 1 1
*Adjusted for age deprivation and time period
doi:10.1371/journal.pone.0122626.t004
Fig 4. Adaptation of Access to Health care pyramid.
doi:10.1371/journal.pone.0122626.g004
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than GP referral (6%) [5]. Due to patient confidentiality, the patients’ details from self-referrals
are not always shared with the GP. The GPs are therefore not always aware when an individual
receives treatment and the treatment would not be recorded in their patient records [5].
Secondly, the highest prevalence of drug users are in the following three groups; prisoners,
homeless and students. The prisoners and homeless may have difficulty registering with a GP
and students may be registered with a different GP during the university term. Data from a
2002 survey found that over 50% of prisoners were not registered with a GP before entering
prison [30], 68%, (n = 1276) of English prisoners reported using an illicit drug the year before
taken into custody [31]. Drug use can often lead to homelessness and about three quarters of
injecting drug users have been homeless at a point in time [7]. With regards to students, ap-
proximately 19.8% of 16–24 years old were found to have used an illicit drug (2011/2012) (4).
Younger, less affluent males are slightly underrepresented in THIN compared to the national
statistics [15].
Thirdly, our results reflect that recording rates are higher for more socially deprived groups.
This may be because there are more people using drugs amongst the socially deprived groups,
but it could also be masking the fact that drug users with less social deprivation could be seek-
ing help elsewhere (e.g. private health care) or denying the problem and avoiding the stigma as-
sociated with drug use [27].
Finally the majority of Read codes used are generic and not specific for a particular drug.
This could be because poly-drug use is common amongst drug users [32]. Symptoms are more
obvious with opiate drug users whilst symptoms of other drugs are not as obvious and could
be missed.
Comparison with existing literature
Gender. With regards to gender, our findings for both drug use and opioid substitute
treatment are similar to both the Crime Survey for England and Wales and the National Treat-
ment Agency [4,5]. Since 1996 there have been 50–60% more male illicit drug users [4]. In
2013, 73% of people in treatment were male [5].
Age-group. Our results regarding age group showed similar patterns to the Crime Survey
for England and Wales, however, the proportion is lower [4]. The younger adults (16–24) were
more likely to be recorded using drugs compared to the older age groups.
In our findings the opioid substitute treatment group is higher in 16–24 year olds until 1999
and then there was an increase in 25–34 years age group. The National Treatment Agency has
reported that opiate use has decreased significantly in the 16–24 year age group and the percent-
age of heroin and methadone users has remained unchanged for the last few years [5]. There-
fore, those seeking opioid substitute treatment are moving into the older age-groups [33].
Social deprivation. Our study illustrates that the higher recording rates of drug use are as-
sociated with more social deprivation. The Crime Survey for England and Wales have found an
inverse association between frequent drug use and income [4]. The Crime Survey for England
andWales has also reported that frequent drug use is higher in urban areas [4]. Likewise, the
opioid substitute treatment is also recorded more in the more socially deprived groups. The
National Treatment Agency has reported that those in treatment are more socially deprived.
Implications for research and/or practice. Our findings show that recording of both drug
use and opioid substitution treatment occurs in primary care, but these figures are lower when
compared to those of the Crime survey for England and Wales and the National Treatment
Agency. GPs are less likely to record if an individual is requiring treatment but either not pre-
senting to the GP and or going elsewhere to receive treatment. There were approximately 197
110 people in treatment in 2011/12 and 81% (n = 159 659) were being treated from heroine
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and /or crack use [33]. This suggests that drug use is identified in primary care, but most drug
users who need treatment do not receive it in primary care. Currently people are in treatment
for General practitioners may be reticent to manage drug dependency in primary care but still
play an integral role in the management of patients’ physical health and people who use drugs
often have poor physical health [34]. Presently the General Medical Service contract does not
have specific Quality and Outcome Framework (QOF) indicators for substance misuse. QOF
indicators could be revised to provide incentives to GPs to identify and treat this vulnerable
group of people. The RCGP have developed a certified course in the management of drug mis-
use which can go some way toward helping GPs to handle these problems [35]. The scope to
develop clear care pathways for those identified in general practice and then treated either in
the practice or referred to an appropriate community drug clinic needs careful consideration.
It is possible that not all GPs would wish to engage with people who use drugs leading to a dis-
parity in the provision of care [36]. Nevertheless, appropriate identification of people who use
drugs by GPs and appropriate management or referral can go some way in ensuring clarity in
the management of this group of people.
We found low level of recording of drug use in general practice notes. It is unclear as why,
when and how GPs record sensitive information of this type on the practice computers and
whether they use specific Read codes for this purpose. A fuller understanding of this phenome-
non would be better investigated through a qualitative study in which a more detailed under-
standing of the methods, classification and circumstances for recording can be explored
together with how to develop a best-practice method of recording drug use on general practice
records [37]
Conclusion
It is evident from this study that there is little recording of drug use and opioid substitute treat-
ment in primary care. Most drug users do not receive treatment in primary care.
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